Compare CERS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | NKTX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 247.4M |
| IPO Year | 1996 | 2020 |
| Metric | CERS | NKTX |
|---|---|---|
| Price | $1.98 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | ★ 1.0M | 937.7K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,326,000.00 | N/A |
| Revenue This Year | $19.95 | N/A |
| Revenue Next Year | $8.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.68 | N/A |
| 52 Week Low | $1.15 | $1.63 |
| 52 Week High | $2.96 | $3.65 |
| Indicator | CERS | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 55.53 |
| Support Level | $1.93 | $1.88 |
| Resistance Level | $2.15 | N/A |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 47.54 | 45.72 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.